| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.61M | $80.75M | +7.3K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 19, 2022 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 500 | $16.74 | $8,370.00 | +0.2% | -47.7% | -33.0% | |
| Feb 11, 2022 | Patel Snehal61 | CEO And CFO | Buy | 5,500 | $19.80 | $108,900.00 | +0.5% | -51.5% | -5.2% | |
| Feb 4, 2022 | Patel Snehal61 | CEO And CFO | Buy | 5,000 | $19.59 | $97,950.00 | +0.4% | -44.0% | +3.6% | |
| Jan 31, 2022 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 500 | $18.47 | $9,235.00 | +0.2% | -39.7% | +7.4% | |
| Jan 21, 2022 | Hallock Kenneth | Director | Buy | 300 | $16.32 | $4,896.00 | - | -2.6% | +7.1% | |
| Jan 21, 2022 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 500 | $16.33 | $8,165.00 | +0.2% | -2.6% | +7.1% | |
| Jan 18, 2022 | Thompson Jaye53 | VP Clinical Reg. Affairs | Buy | 500 | $18.87 | $9,435.00 | +0.2% | -13.8% | -13.5% | |
| Jan 13, 2022 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $19.99 | $19,990.00 | - | -11.2% | -18.7% | |
| Jan 13, 2022 | Thompson Jaye53 | VP Clinical Reg. Affairs | Buy | 1,000 | $19.99 | $19,990.00 | +0.4% | -11.2% | -18.7% | |
| Jan 13, 2022 | Daugherty Frank Joseph | Chief Medical Officer | Buy | 1,000 | $19.99 | $19,990.00 | +1.1% | -11.2% | -18.7% |